


I hereby certify that this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231

Date of Signature
and Deposit:

9/27/05



Jean C. Baker, Registration No. 35,433

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application. No.: 10/014,724
Applicants: Michael N. Gould, et al.
Filed: November 7, 2001
Title: MONOTERPENES AND SESQUITERPENES AS
CHEMOTHERAPEUTIC AND RADIATION SENSITIZERS AND
IMMUNOMODULATORS
Art Unit: 1618
Examiner: Dameron L. Jones
File No.: 960296.97711

Commissioner for Patents
P O Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. 1.98, enclosed herewith is a list of documents which the Applicants in the above-identified patent application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this patent application.

The information listed in the accompanying Form PTO-1449 and provided herewith may be material to the above-identified application and is submitted in compliance with the requirements of 37 C.F.R. §1.56.

Other Documents

Broitman SA, *et al.*, "Effects of monoterpenes and mevinolin on murine colon tumor CT-26 *in vitro* and its hepatic 'metastases' *in vivo*," Adv. Exp. Med. Biol. 401:111-130,

1996.

10/03/2005 HDESTA1 00000104 170055 10014724

03 FC:1806 180.00 DA

Chen Y and Hu D, "Effects of POH in combination with STI571 on the proliferation and apoptosis of K562 cells," J. Huazhon Univ. Sci. Technolog. Med. Sci. 24(1):41, 2004.

Hyer ML, *et al.*, "Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells," Cancer Res. 65(11):4799-4808, 2005.

Keane MM, *et al.*, "Chemotherapy augments TRAIL-induced apoptosis in breast cell lines," Cancer Res. 59(3):734-741, 1999.

Mo H and Elson CE, "Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention," pp. 567-585, 2004.

Rajesh D, *et al.*, "Perillyl alcohol as a radio-/chemosensitizer in malignant glioma," J. Biol. Chem. 278(38):35968-35978, 2003.

Shi B, *et al.*, "The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes *in vitro* and enhances their antitumor activity *in vivo*," Cancer Chemother. Pharmacol. 46:387-393, 2000.

Vigushin DM, *et al.*, "Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee," Cancer Chemother. Pharmacol. 42(2):111-117, 1998.

Yu D, "Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers," 28(Suppl. 16):12-17, 2001.

Zhang S, *et al.*, "Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms," Curr. Med. Chem. Anti-Canc. Agents 5(3):239, 2005.

International Agency for Research on Cancer (IARC) – Summaries & Evaluations, Lumber and Sawmill Industries (Including Logging) (Group 3) Suppl 7:383, 1987.


Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 17-0055.

No additional fees are believed necessary to enter this statement. However, if a fee is necessary please charge Deposit Account No. 17-0055.


Respectfully submitted,

Michael N. Gould, et al.

Sept 27
~~October~~ __, 2005

By: 

Jean C. Baker
Reg. No. 35,433
QUARLES & BRADY LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202-4497
(414) 277-5633
(414) 271-3552



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Submittal to PTO Form 49A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/014,724
Filing Date	November 7, 2001
First Named Inventor	Michael N. Gould
Art Unit	1618
Examiner Name	Dameron L. Jones
Attorney Docket Number	960296.97711

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

Examiner
Signature


Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

5794512_1.PDF



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08b (07-05)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

3

Complete if Known

Application Number	10/014,724
Filing Date	November 7, 2001
First Named Inventor	Michael N. Gould
Art Unit	1618
Examiner Name	Dameron L. Jones
Attorney Docket Number	960296.97711

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Broitman SA, et al., "Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic 'metastases' in vivo," Adv. Exp. Med. Biol. 401:111-130, 1996.	
		Chen Y and Hu D, "Effects of POH in combination with STI571 on the proliferation and apoptosis of K562 cells," J. Huazhon Univ. Sci. Technolog. Med. Sci. 24(1):41, 2004.	
		Hyer ML, et al., "Synthetic triterpenoids cooperates with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells," Cancer Res. 65(11):1700-1708, 2005.	
		Keane MM, et al., "Chemotherapy augments TRAIL-induced apoptosis in breast cell lines," Cancer Res. 59(3):734-741, 1999.	
		Mo H and Elson CE, "Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention," pp. 567-585, 2004.	
		Rajesh D, et al., "Perillyl alcohol as a radio-/chemosensitizer in malignant glioma," J. Biol. Chem. 278(38):35968-35978, 2003.	
		Shi B, et al., "The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo," Cancer Chemother. Pharmacol. 46:387-393, 2000.	
		Vigushin DM, et al., "Phase I and pharmacokinetic study of D-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee," Cancer Chemother. Pharmacol. 42(2):111-117, 1998.	
		Yu D, "Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers," 28(Suppl. 16):12-17, 2001.	
		Zhang S, et al., "Anti-cancer potential of sesquiterpene lactones: bioactivity and molecular mechanisms," Curr. Med. Chem. Anti-Canc. Agents 5(3):239, 2005.	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

5794512_1.PDF



PTO/SB/08b (07-05)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Complete if Known

(Use as many sheets as necessary)

Sheet

3

of

3

Application Number

10/014,724

Filing Date

November 7, 2001

First Named Inventor

Michael N. Gould

Art Unit

1618

Examiner Name

Dameron L. Jones

Attorney Docket Number

960296.97711

NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.